Trump Administration Defends Cannabis Schedule III Classification Amid Ongoing Debate

During initial hearings on cannabis rescheduling, the U.S. Government presented testimony supporting Schedule III classification, highlighting medical benefits and comparing cannabis risks favorably to alcohol and opioids. The testimony addressed therapeutic applications while acknowledging safety profiles relevant to patients considering medical cannabis. This defense comes as the rescheduling debate continues among policymakers, medical professionals, and patient advocacy groups. The comparative risk analysis presented may influence how medical professionals and patients in Puerto Rico view cannabis as a therapeutic option. The outcome of these hearings could impact access to medical cannabis for patients with qualifying conditions.